Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …

Background Bortezomib-based induction followed by high-dose melphalan (200 mg/m 2)
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background Adult-onset inflammatory syndromes often manifest with overlapping clinical
features. Variants in ubiquitin-related genes, previously implicated in autoinflammatory …

Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen
(BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells …